IPO - Odyssey Therapeutics, Inc.

Form Type: S-1

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000119312525008362

Filing Summary: Odyssey Therapeutics, Inc. is filing a registration statement for an initial public offering (IPO) of their common stock, aiming to raise funds to further develop their biopharmaceutical innovations targeting autoimmune and inflammatory diseases. The IPO is anticipated to feature shares being offered for sale to the public with plans to list on the Nasdaq Capital Market under the symbol 'ODTX.' The company emphasizes its focus on therapeutics designed to selectively target innate immune system pathways, distinguishing its approach from existing therapies that primarily inhibit cytokines, thus addressing the limitations in current treatments for diseases like inflammatory bowel disease (IBD). The document outlines the company's product pipeline, including key candidates such as OD-07656, a small molecule targeting RIPK2 for ulcerative colitis, which is poised to enter Phase 2 trials in early 2025. Odyssey Therapeutics also highlights its differentiation through deep expertise in immunobiology and a commitment to advancing the understanding and treatment of significant health conditions in this space. The offering is part of the company’s strategy to establish itself as a leading firm in the biopharmaceutical industry, focusing on discovering and bringing transformative therapies to market for unmet medical needs in immunology.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-12-05

Corporate Action: Ipo

Type: New

Accession Number: 000095012324012178

Filing Summary: Odyssey Therapeutics, Inc. is filing an amendment to its draft registration statement for an initial public offering (IPO) of shares of common stock, with the intent to list on the Nasdaq Capital Market under the symbol 'ODTX'. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for autoimmune and inflammatory diseases. Their leading drug candidate, OD-07656, an inhibitor targeting RIPK2, is set to enter Phase 2a trials for ulcerative colitis in 2025. The filing provides critical details regarding the public offering's terms, risks, and potential market impact, emphasizing the company’s strategy to deliver innovative treatments addressing significant unmet medical needs. The stock offering is anticipated to begin as soon as the registration is effective.

Document Link: View Document

Form Type: DRS/A

Filing Date: 2024-11-18

Corporate Action: Ipo

Type: New

Accession Number: 000095012324012003

Filing Summary: Odyssey Therapeutics, Inc. is filing an initial public offering (IPO) of its common stock, with an estimated price range per share to be determined. The company aims to list its shares on the Nasdaq Capital Market under the symbol 'ODTX.' The registration statement filed is Amendment No. 1, submitted confidentially on November 15, 2024. Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases, with several product candidates in development, including OD-07656, an oral small molecule RIPK2 scaffolding inhibitor for ulcerative colitis, and others targeting IRAK4 and TNFR2. The company plans to conduct various clinical trials globally and has highlighted a diversified strategy for growth through development, collaboration, and investment in innovation.

Document Link: View Document

Form Type: DRS

Filing Date: 2024-10-07

Corporate Action: Ipo

Type: New

Accession Number: 000095012324009534

Filing Summary: Odyssey Therapeutics, Inc. has filed a draft registration statement for an initial public offering (IPO) of its common stock under Form S-1, which has not been publicly filed yet. The registration statement includes preliminary information about the offering, stating that this is the first public sale of its common stock with no prior public market for the stock. The expected price per share for the IPO is projected to be within a specified range that is to be determined. The company plans to list the stock on the Nasdaq Capital Market under the symbol 'ODTX'. The offering aims to raise capital for advancing its clinical-stage biopharmaceutical programs targeting autoimmune and inflammatory diseases, specifically focusing on products like OD-07656, an inhibitor for ulcerative colitis; IRAK4 inhibitors; and a TNFR2 targeting therapy designed for regulatory T cell modulation. The IPO's success hinges on achieving Nasdaq listing standards, with the anticipated commencement of sales following the registration effectiveness.

Document Link: View Document